These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22050678)

  • 1. Current drug design of anti-HIV agents through the inhibition of C-C chemokine receptor type 5.
    Speck-Planche A; Cordeiro MN
    Curr Comput Aided Drug Des; 2011 Dec; 7(4):238-48. PubMed ID: 22050678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.
    Mohamed H; Gurrola T; Berman R; Collins M; Sariyer IK; Nonnemacher MR; Wigdahl B
    Front Immunol; 2021; 12():816515. PubMed ID: 35126374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV co-receptor CCR5: structure and interactions with inhibitors.
    Wang T; Duan Y
    Infect Disord Drug Targets; 2009 Jun; 9(3):279-88. PubMed ID: 19519482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
    Seibert C; Sakmar TP
    Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine receptor-directed agents as novel anti-HIV-1 therapies.
    Mills SG; DeMartino JA
    Curr Top Med Chem; 2004; 4(10):1017-33. PubMed ID: 15193136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent updates for designing CCR5 antagonists as anti-retroviral agents.
    Shah HR; Savjani JK
    Eur J Med Chem; 2018 Mar; 147():115-129. PubMed ID: 29425816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 entry inhibitors: classes, applications and factors affecting potency.
    Sterjovski J; Churchill MJ; Wesselingh SL; Gorry PR
    Curr HIV Res; 2006 Oct; 4(4):387-400. PubMed ID: 17073614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5 chemokine receptors: gatekeepers of HIV-1 infection.
    Kazmierski WM; Boone L; Lawrence W; Watson C; Kenakin T
    Curr Drug Targets Infect Disord; 2002 Sep; 2(3):265-78. PubMed ID: 12462129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress on chemokine receptor 5-targeted therapy for HIV-1].
    Wang YJ; Zhang JQ
    Bing Du Xue Bao; 2014 Jan; 30(1):79-83. PubMed ID: 24772903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances of CCR5 antagonists: From small molecules to macromolecules.
    Qi B; Fang Q; Liu S; Hou W; Li J; Huang Y; Shi J
    Eur J Med Chem; 2020 Dec; 208():112819. PubMed ID: 32947226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting chemokine receptors for HIV: past, present and future.
    Fricker SP
    Future Med Chem; 2015; 7(17):2311-5. PubMed ID: 26627446
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CCR5, a new target of anti-HIV drugs].
    Han YX; Jiang JD
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):635-9. PubMed ID: 14650176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-receptor antagonists as HIV-1 entry inhibitors.
    Shaheen F; Collman RG
    Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
    Peng P; Chen H; Zhu Y; Wang Z; Li J; Luo RH; Wang J; Chen L; Yang LM; Jiang H; Xie X; Wu B; Zheng YT; Liu H
    J Med Chem; 2018 Nov; 61(21):9621-9636. PubMed ID: 30234300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise of CCR5 antagonists as new therapies for HIV-1.
    Repik A; Richards KH; Clapham PR
    Curr Opin Investig Drugs; 2007 Feb; 8(2):130-9. PubMed ID: 17328229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CB-0821, a novel CC chemokine receptor 5 (CCR5) inhibitor with improved binding efficacy proposed as anti-HIV candidate: Computational and in vitro approach.
    Kumar A
    Biotechnol Appl Biochem; 2024 Aug; 71(4):849-859. PubMed ID: 38556770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.